Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.

Antiviral therapy - 1 Jan 2012

Wang Xue-Yan, Wei Zhen-Man, Wu Guo-Yi, Wang Jiang-Hua, Zhang Ying-Jun, Li Jing, Zhang Heng-Hui, Xie Xing-Wang, Wang Xian, Wang Zhao-He, Wei Lai, Wang Yu, Chen Hong-Song

Abstract excerpt

BACKGROUND: HBV infection continues to be an important worldwide cause of morbidity and mortality. Patients with chronic hepatitis B can be successfully treated using nucleoside/nucleotide analogues. However, drug-resistant HBV mutants frequently arise, leading to treatment failure and progression to liver disease. Here, we report the effects of GLS4, a non-nucleosidic inhibitor that exhibits a novel and highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Capsid Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Inhibitory Concentration 50

Share to Organophosphonates

Share to Thiazoles

Share to Viral Core Proteins

Share to Virus Assembly

Source

Identifiers

PMID: 22668794
DOI: 10.3851/IMP2152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.PMID 22668794Read ↗

Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and PerspectivesSemantic proximity Read ↗

Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.Semantic proximity Read ↗

Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus.Semantic proximity Read ↗

Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.Semantic proximity Read ↗

Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.Semantic proximity Read ↗

Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticSemantic proximity Read ↗

Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profilesSemantic proximity Read ↗

Host poly(A) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNASemantic proximity Read ↗

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Semantic proximity Read ↗

New potent biaryl sulfate-based hepatitis C virus inhibitors.Semantic proximity Read ↗

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.Semantic proximity Read ↗

Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.